An antibody response to a protein therapeutic can compromise drug exposure and lead to an altered safety profile. As a result, the immunogenicity of therapeutic proteins requires investigation during their development. Prevalere offers quantitative and qualitative assays for detection of anti-drug antibodies in biological fluids.
Immunogenicity Services:
- Oversight of positive control anti-serum production
- Purification of reference standard
- Development of bridging or direct ELISA assays for detection of anti-drug antibodies
- Immunodepletion analysis
- Antibody Isotyping
- Neutralization Assays
